Press Releases

CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, today announced that its Risk-Based Quality Management (RBQM) platform has been critical in supporting numerous Pharmaceutical companies and CROs to interrogate data...

As scientists continue to identify new strains of the SARS-CoV-2 virus, including the B.1.1.7 UK variant that studies suggest is more transmissible, genetic sequencing is being used to track these strains and new ones that are emerging, as well...

Since Christmas, DHL Express, the worldwide leading express service provider, has operated more than 50 flights transporting numerous shipments of the urgently needed COVID-19 vaccines within Europe. Destinations included are Austria, Bulgaria, Croatia, Greece, Finland, Italy, Lithuania, Norway, Romania...

Baxter International Inc., a global leader in sterile medication production and delivery, announced that Baxter BioPharma Solutions has entered into an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M™ adjuvant. Baxter...

FUJIFILM Diosynth Biotechnologies and the Texas A&M University System Center for Innovation in Advanced Development & Manufacturing (CIADM) announced that production has begun in Texas on two different COVID-19 vaccine candidates with support from the U.S. government to meet...

In line with the need for pharmaceutical research, cell and gene therapy, vaccine production and biobanking laboratories for dependable sample protection, the new series of controlled-rate freezers from Thermo Fisher Scientific provides precise, repeatable freezing capabilities, while enhancing data...

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved its mRNA vaccine against COVID-19 (COVID-19 Vaccine Moderna) for use under Regulation 174. The...